Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Randomized, Placebo Controlled Study of the Monophasic Oral Contraceptive YAZ (20 µg Ethinylestradiol, 3 mg Drospirenone) in the Treatment of Chinese Patients With Premenstrual Dysphoric Disorder (PMDD)
Conditions
Interventions
EE20/DRSP(YAZ, BAY86-5300)
Placebo
Locations
16
China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Wuhan, Hubei, China
Changsha, Hunan, China
Nanjing, Jiangsu, China
Dalian, Liaoning, China
Start Date
January 1, 2009
Primary Completion Date
January 1, 2011
Completion Date
January 1, 2011
Last Updated
April 2, 2014
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions